Testing treatment effects in the presence of competing risks

Statistics in Medicine

Volumn 24, Issue 11, 2005, Pages 1703-1712

  Freidlin, Boris ^a   Korn, Edward L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cause specific hazard; Competing risks; Cumulative incidence; Latent failure time model

Indexed keywords

ANTINEOPLASTIC AGENT;

ANALYTIC METHOD; CLINICAL RESEARCH; CLINICAL TRIAL; CORRELATION ANALYSIS; HUMAN; INTERMETHOD COMPARISON; MATHEMATICAL COMPUTING; RELIABILITY; REVIEW; RISK ASSESSMENT; SAMPLE SIZE; SIMULATION; SOLID TUMOR; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TREATMENT FAILURE;

COMPUTER SIMULATION; HEAD AND NECK NEOPLASMS; HUMANS; MODELS, BIOLOGICAL; MODELS, STATISTICAL; NEOPLASM RECURRENCE, LOCAL; RADIOTHERAPY; RISK FACTORS; TREATMENT OUTCOME;

EID: 19944418263     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/sim.2054     Document Type: Review

References (40)

1. Moeschberger ML, David HA. Life tests under competing causes of failure and the theory of competing risks. Biometrics 1971; 27:909-933.
2. Makeham WM. On an application of the theory of the composition of the decremental forces. Journal of the Institute of Actuaries 1874; 18:317-322.
3. Cornfield J. The estimation of the probability of developing a disease in the presence of competing risks. American Journal of Public Health 1957; 47:601-607.
4. Cox DR. The analysis of exponentially distributed lifetimes with two types of failure. Journal of the Royal Statistical Society, Series B 1959; 21:411-421.
5. Prentice RL, Kalbfleisch JD, Peterson AV, Flournoy N, Farewell VT, Breslow NE. The analysis of failure times in the presence of competing risks. Biometrics 1978; 34:541-554.
6. Schatzkin A, Slud E. Competing risks bias arising from omitted risk factor. American Journal of Epidemiology 1989; 129:850-856.
7. Tsiatis A. A nonidentifiability aspect of the problem of competing risks. Proceedings of the National Academy of Sciences 1975; 72:20-22.
8. Aalen O. Nonparametric inference in connection with multiple decrement models. Scandinavian Journal of Statistic 1976; 3:15-27.
9. Peterson AV. Bounds for a joint distribution function with fixed subdistribution functions: application to competing risks. Proceedings of the National Academy of Sciences 1976; 73:11-13.
10. Kay R, Schumacher M. Unbiased assessment of treatment effects on disease recurrence and survival in clinical trials. Statistics in Medicine 1983; 2:41-58.
11. Slud E, Rubinstein L. Dependent competing risks and summary survival curves. Biometrika 1983; 70:643-649.
12. Kay R. Treatment effects in competing risks analysis of prostate cancer data. Biometrics 1986; 42:203-211.
13. Slud E, Byar D. How dependent causes of death can make risk factors appear protective. Biometrics 1988; 44:265-269.
14. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of competing risks. Annals of Statistics 1988; 16:1141-1154.
15. Pepe MS. Inference for events with dependent risks in multiple endpoint studies. Journal of the American Statistical Association 1991; 86:770-778.
16. Korn EL, Dorey FJ. Applications of crude incidence curves. Statistics in Medicine 1992; 11:813-829.
17. Pepe MS, Mori M. Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure data? Statistics in Medicine 1993; 12:737-751.
18. Gaynor JJ, Feuer EJ, Tan CC, Wu DH, Little CR, Straus DJ, Clarkson BD, Brennan MF. On the use of cause-specific failure and conditional failure probabilities: examples from clinical oncology data. Journal of the American Statistical Association 1993; 88:400-409.
19. Lunn M, McNeil D. Appling Cox regression to competing risks. Biometrics 1995; 51:524-532.
20. Faraggi D, Korn EL. Competing risks with frailty models when treatment affects only one failure type. Biometrika 1996; 83:467-471.
21. Lin DY. Non-parametric inference for cumulative incidence functions in competing risks studies. Statistics in Medicine 1997; 16:901-910.
22. Pintilie M. Dealing with competing risks: testing covariates and calculating sample size. Statistics in Medicine 2002; 21:3317-3324.
23. Caplan RJ, Pajak TF, Cox JD. Analysis of the probability and risk of cause-specific failure. International Journal of Radiation Oncology Biology and Physics 1994; 29:1183-1186.
24. Gail M. A review and critique of some models used in competing risk analysis. Biometrics 1975; 31:209-222.
25. Marubini E, Valsecchi MG. Analyzing Survival Data from Clinical and Observational Studies. Wiley: New York, 1995.
26. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. Journal of the Royal Statistical Society, Series A 1972; 135:185-207.
27. Oakes D. A model for association in bivariate survival data. Journal of the Royal Statistical Association, Series B 1982; 3:414-422.
28. Genest C. Frank's family of bivariate distributions. Biometrika 1987; 74:549-555.
29. Morris M, Eifel PJ, Lu J et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and paraaortic radiation for high risk cervical cancer. The New England Journal of Medicine 1999; 340:1137-1143.
30. Fu KK, Pajak TF, Trotti A et al. A RTOG phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinoma. International Journal of Radiation Oncology Biology and Physics 2000; 48:7-16.
31. Pilepich MV, Winter K, John MJ et al. Phase III RTOG trial 8610 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of prostate. International Journal of Radiation Oncology Biology and Physics 2001; 50:1243-1252.
32. Forastiere AA, Goepfert H, Maor M et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. The New England Journal of Medicine 2003; 349:2091-2098.
33. Lowton CA, Winter K, Murray K et al. Updated results of the phase III RTOG trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of prostate. International Journal of Radiation Oncology Biology and Physics 2001; 49:937-946.
34. Borner MM, Bacchi M, Castiglione M. Possible deleterious effect of tamoxifen in premenopausal women with locoregional recurrence of breast cancer. European Journal of Cancer 1996; 12:2173-2176.
35. Waeber M, Castiglione-Gertsch M, Dietrich D et al. Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence. Annals of Oncology 2003; 14:1215-1221.
36. Crivellari D, Price K, Gelber RD et al. Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-year results of international breast cancer study group trial IV. Journal of Clinical Oncology 2003; 21:4517-4523.
37. Keller SM, Vangel MG, Wagner H et al. Second primary tumors following adjuvant therapy of resected stages II and IIIa non-small cell lung cancer. Lung Cancer 2003; 42:79-86.
38. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data (2nd edn). Wiley: New York, 2002; 252.
39. Gelman R, Gelber R, Henderson C, Coleman CN, Harris JR. Improved methodology for analyzing local and distant recurrence. Journal of Clinical Oncology 1990; 8:548-555.
40. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Statistics in Medicine 1999; 18:695-706.